
# depot <img src = "vignette/img/mrgsolve_hex.png" align="right" width="120px"></img>

## azithro

  - Type: Population PK
  - Links: [model](pkg/inst/models/azithro.cpp)
    [vignette](vignette/azithro.md)

**Reference** Zhao Q, Tensfeldt TG, Chandra R, Mould DR. *Population
pharmacokinetics of azithromycin and chloroquine in healthy adults and
paediatric malaria subjects following oral administration of fixed-dose
azithromycin and chloroquine combination tablets*. Malar J. 2014 Jan
29;13:36. <doi:10.1186/1475-2875-13-36>. PubMed PMID: 24472224; PubMed
Central PMCID: PMC3909452.

## cipro

  - Type: PBPK
  - Links: [model](pkg/inst/models/cipro.cpp)
    [vignette](vignette/cipro.md)

**Reference** Sadiq MW, Nielsen EI, Khachman D, Conil JM, Georges B,
Houin G, Laffont CM, Karlsson MO, Friberg LE. A whole-body
physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin:
a step towards predicting bacterial killing at sites of infection. J
Pharmacokinet Pharmacodyn. 2017 Apr;44(2):69-79. doi:
10.1007/s10928-016-9486-9. Epub 2016 Aug 30. PubMed PMID: 27578330;
PubMed Central PMCID: PMC5376394.

## gcsf

  - Type: TMDD
  - Links: [model](pkg/inst/models/gcsf.cpp)
    [vignette](vignette/gcsf.md)

**Reference** Krzyzanski W, Wiczling P, Lowe P, Pigeolet E, Fink M,
Berghout A, Balser S. Population modeling of filgrastim PK-PD in healthy
adults following intravenous and subcutaneous administrations. J Clin
Pharmacol. 2010 Sep;50(9 Suppl):101S-112S. doi:
10.1177/0091270010376966. PubMed PMID: 20881223.

## sunit

  - Type: Population PK
  - Links:[model](pkg/inst/models/sunit.cpp)
    [vignette](vignette/sunit.md)

**Reference** Houk BE, Bello CL, Kang D, Amantea M. A population
pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its
primary metabolite (SU12662) in healthy volunteers and oncology
patients. Clin Cancer Res. 2009 Apr 1;15(7):2497-506. doi:
10.1158/1078-0432.CCR-08-1893. Epub 2009 Mar 3. PubMed PMID: 19258444.

## secukinumab

  - Type: PK/PD
  - Links: [model](pkg/inst/models/secukinumab.cpp)
    [vignette](vignette/secukinumab.md)

**Reference**

FDA Clin Pharm Review 125504Orig1s000ClinPharmR.pdf

  - Clinical Pharmacology Reviewer: Jie Wang, Ph.D.
  - Pharmcometrics Reviewer: Jee Eun Lee, Ph.D.
  - Pharmacometrics Team Leader: Jeffry Florian, Ph.D.
  - Clinical Pharmacology Team Leader: Yow-Ming Wang,
Ph.D.

<https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125504Orig1s000ClinPharmR.pdf>

## rifampicin

  - Type: PBPK
  - Links: [model](pkg/inst/models/rifampicin.cpp)
    [vignette](vignette/rifampicin.md)

**Reference** Asaumi R, Toshimoto K, Tobe Y, Hashizume K, Nunoya KI,
Imawaka H, Lee W, Sugiyama Y. Comprehensive PBPK Model of Rifampicin for
Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9
Induction and OATP Inhibition Effects. CPT Pharmacometrics Syst
Pharmacol. 2018 Mar;7(3):186-196. doi: 10.1002/psp4.12275. Epub 2018 Feb
5. PubMed PMID: 29368402; PubMed Central PMCID: PMC5869557.

## moxi

  - Type: Population PK
  - Links: [model](pkg/inst/models/moxi.cpp)
    [vignette](vignette/moxi.md)

**Reference** Wicha SG, Haak T, Zink K, Kees F, Kloft C, Kees MG.
Population pharmacokinetics and target attainment analysis of
moxifloxacin in patients with diabetic foot infections. J Clin
Pharmacol. 2015 Jun;55(6):639-46. <doi:10.1002/jcph.464>. Epub 2015 Feb
13. PubMed PMID: 25600294.
